Levofloxacin
Regulatory milestones approvals, filings & regulatory actions · 15 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Quinsair | — | 2015-03-25 | europa.eu ↗ |
| Label expansions (13) | US (FDA) | LEVAQUIN | — | 1998-12-17 – 2012-04-27 | fda.gov ↗ |
| Approved | US (FDA) | LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER | — | 1996-12-20 | fda.gov ↗ |
Trials 190 · started per year
Also used as a comparator or background therapy in 142 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06810583 Background | May 2025 → Sep 2030 expected | acute myeloid leukemia, childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05741632 Comparator | Feb → Mar 2023 | cataract | Indonesia University | Completed | No outcome recorded |
| Phase 1 | NCT01500382 Background | Feb 2012 → Jan 2013 | overactive bladder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01169038 Comparator | Jul → Nov 2010 | pulmonary sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT00362869 Background | Feb → Aug 2008 | escherichia coli infection | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06889701 Background | Apr 2025 → Aug 2026 overdue | periprosthetic joint infection | TenNor Therapeutics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04214821 Comparator | Sep 2019 → Aug 2021 | endophthalmitis | National University of Malaysia | Unknown | No outcome recorded |
| Phase 1/2 | NCT04212429 Comparator | Sep 2019 → Aug 2021 | endophthalmitis | National University of Malaysia | Unknown | No outcome recorded |
| Phase 1/2 | NCT04212078 Comparator | Jul 2019 → Jan 2022 | endophthalmitis | National University of Malaysia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02148016 Background | Dec 2012 → Jun 2014 | hyperopia, myopia, pterygium | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT07170800 Background | Sep 2025 → Feb 2026 overdue | multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | WestVac Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07150065 Comparator | Feb → Aug 2025 | typhoid fever | Avicenna Medical College Lahore | Completed | No outcome recorded |
| Phase 2 | NCT06616922 Comparator | Nov 2021 → Jun 2023 | bacterial conjunctivitis | NTC srl | Completed | No outcome recorded |
| Phase 2 | NCT03757234 Comparator | Nov 2018 → Jun 2019 | acute pyelonephritis | Paratek Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 2 | NCT03740659 Comparator | Sep → Dec 2018 | cataract | NTC srl | Completed | No outcome recorded |
| Phase 2 | NCT02789865 Comparator | May 2016 → Apr 2018 | appendicitis | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 2 | NCT03201796 Comparator | Feb 2016 → May 2020 | chronic prostatitis | Angelini Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2 | NCT02024555 Comparator | Mar 2014 → Apr 2019 | sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT03159845 Background | Jan 2014 → Sep 2019 | disease related to hematopoietic stem cell transplant | Azienda Ospedaliero, Universitaria Pisana | Completed | No outcome recorded |
| Phase 2 | NCT01756924 Comparator | Dec 2012 → Jul 2014 | periprosthetic joint infection | Arrevus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01805934 Comparator | May → Dec 2012 | — | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01168713 Comparator | Aug 2010 → Jul 2011 | bacterial pneumonia | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01096849 Comparator | Jul 2010 → Apr 2012 | acute pyelonephritis | Achaogen, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01081964 Comparator | Mar 2010 → Apr 2012 | — | IASO Pharma Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00659646 Comparator | Apr 2008 → May 2009 | ulcer of lower limbs | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT00593567 Comparator | Dec 2007 → May 2009 | ulcer of lower limbs | Innocoll | Completed | No outcome recorded |
| Phase 2 | NCT00516958 Comparator | May → Dec 2007 | ulcer of lower limbs | Oculus Innovative Sciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00250718 Background | Oct 2004 → Nov 2008 | cancer, non-Hodgkin lymphoma | New Mexico Cancer Research Alliance | Terminated | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT06568484 Comparator | May 2026 → Jul 2027 expected | latent tuberculosis infection | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06859450 Comparator | Mar → Sep 2025 overdue | pneumonia | Copenhagen Respiratory Research | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03622450 Comparator | Jan 2016 → Jan 2018 | — | Nourhan Hassan Osama Thuraya Mohamed | Completed | No outcome recorded |
| Phase 2/3 | NCT00789997 Background | Nov 2008 → Aug 2011 | chronic obstructive pulmonary disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00565123 Comparator | Sep 2004 → Jan 2006 | bacterial conjunctivitis | Laser Microsurgery Centre, Poland | Completed | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT06760065 Comparator | Jan 2025 → Dec 2027 expected | Helicobacter pylori infectious disease | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06684626 Background | Mar → Jul 2024 | chronic prostatitis | Federico II University | Completed | No outcome recorded |
| Phase 3 | NCT06081361 Background | Dec 2023 → Oct 2026 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06414707 Comparator | Oct 2023 → Apr 2024 | Helicobacter pylori infectious disease | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05728424 Comparator | Sep 2022 → Apr 2023 | Helicobacter pylori infectious disease | Aga Khan University | Unknown | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT06101420 Background | Jan 2022 → Jun 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05863858 Comparator | Jun 2020 → Dec 2021 | Helicobacter pylori infectious disease | Iyad Naeem Muhammad, PhD | Completed | No outcome recorded |
| Phase 3 | NCT03862248 Comparator | Sep 2019 → Oct 2022 | pulmonary tuberculosis | Institute of Tropical Medicine, Belgium | Withdrawn | No outcome recorded |
| Phase 3 | NCT04062201 Comparator | Aug 2019 → Apr 2024 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Wits Health Consortium (Pty) Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03688295 Comparator | Feb 2019 → Sep 2025 overdue | appendicitis | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT03409679 Comparator | Mar 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03032510 Background | Jan → Dec 2017 | urinary tract infection | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT03551210 Comparator | May 2016 → Dec 2017 | bacterial pneumonia | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT02809131 Comparator | Apr 2016 → Mar 2021 | sick sinus syndrome, systolic heart failure, third-degree atrioventricular block | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02717871 Comparator | Mar 2016 → Oct 2020 | keratitis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 3 | NCT02486627 Background | Jan → Sep 2016 | acute pyelonephritis | Achaogen, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02166476 Background | Nov 2014 → Apr 2016 | acute pyelonephritis | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01978938 Comparator | Oct 2014 → Jun 2015 | urinary tract infection | Tetraphase Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02205112 Comparator | Jun 2014 → May 2017 | pneumonia | TaiGen Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02120638 Comparator | Apr 2014 → Apr 2016 | multidrug-resistant tuberculosis | Huashan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01988779 Comparator | Oct 2013 → Sep 2017 | chronic rhinosinusitis | University of Rochester | Completed | No outcome recorded |
| Phase 3 | NCT02157571 Comparator | Jun 2013 → Jun 2014 | chronic bronchitis | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 3 | NCT01345929 Comparator | Jun 2011 → Aug 2013 | pyelonephritis | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01529476 Comparator | Apr 2011 → Aug 2012 | pneumonia | TaiGen Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01109823 Comparator | May 2010 → Dec 2013 | infectious disease | University Ghent | Completed | No outcome recorded |
| Phase 3 | NCT01055145 Comparator | Mar 2010 → Jul 2012 | tuberculosis | Seoul National University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00453349 Comparator | Jan 2007 → May 2008 | pelvic inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00402688 Comparator | Nov 2006 → Mar 2008 | chronic prostatitis | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00431678 Comparator | Jan 2004 → Jul 2005 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase 450 trials | ||||||
| Phase 4 | NCT07537634 Background | Apr → Aug 2026 overdue | Helicobacter pylori infectious disease, dyspepsia, peptic ulcer disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting | No outcome recorded |
| Phase 4 | NCT07405697 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405684 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07021729 Comparator | Dec 2025 → Mar 2026 overdue | Helicobacter pylori infectious disease | Rehman Medical Institute - RMI | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06200779 Comparator | Sep 2025 → Sep 2026 expected | Helicobacter pylori infectious disease | Manuel Coelho da Rocha | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07344506 Background | May 2025 → May 2026 overdue | Helicobacter pylori infectious disease | Dow University of Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT06351891 Comparator | Apr → Dec 2024 | Helicobacter pylori infectious disease | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT06065267 Comparator | Jan 2024 → Dec 2026 expected | Helicobacter pylori infectious disease | Damascus Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT06172010 Comparator | Apr 2023 → Mar 2027 expected | periprosthetic joint infection | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06088316 Comparator | Feb 2023 → Feb 2024 | Helicobacter pylori infectious disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 4 | NCT05575427 Background | Nov 2022 → Jul 2024 | nosocomial infection | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT05393505 Background | Oct 2022 → Mar 2025 | neutropenia | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT05306223 Background | May 2022 → Aug 2025 | multidrug-resistant tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05313750 Comparator | Jun 2021 → Dec 2023 | bronchiectasis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 4 | NCT04660123 Background | Dec 2020 → Dec 2021 | Helicobacter pylori infectious disease, gastric cancer | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT04626193 Comparator | Oct 2020 → Dec 2023 | Helicobacter pylori infectious disease | Damascus Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04502095 Background | Sep 2020 → Mar 2025 | urinary bladder carcinoma, urinary tract infection | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 4 | NCT04204382 Background | Dec 2019 → Sep 2022 | mucositis | Shanxi Zhendong Pharmacy Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT04348786 Comparator | Feb 2019 → Aug 2020 | Helicobacter pylori infectious disease | Damascus Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03658746 Comparator | Jan → Dec 2019 | Helicobacter pylori infectious disease | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT03658291 Comparator | Jan → Jun 2019 | urinary tract infection | China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT03619252 Comparator | Jul 2018 → Jan 2021 | bacterial pneumonia, neutropenia, plasma cell myeloma, pneumococcal infection | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Completed | No outcome recorded |
| Phase 4 | NCT04039412 Comparator | Jun → Dec 2018 | Helicobacter pylori infectious disease | Ayman Magd Eldin Mohammad Sadek | Completed | No outcome recorded |
| Phase 4 | NCT03220074 Background | Dec 2017 → Jun 2021 | mycobacterial infectious disease | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT03021590 Comparator | Jun 2017 → Dec 2021 | Helicobacter pylori infectious disease | Damascus Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT03160807 Comparator | Apr 2017 → Mar 2018 | urinary tract infection | Dr. Reddy's Laboratories Limited | Unknown | No outcome recorded |
| Phase 4 | NCT03087656 Comparator | Mar 2017 → Feb 2024 | cholangitis | University of Southern California | Unknown | No outcome recorded |
| Phase 4 | NCT03038321 Comparator | Feb → Dec 2017 | cystitis, non-invasive bladder urothelial carcinoma | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT03391440 Background | Sep 2016 → Dec 2018 | pelvic inflammatory disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02618057 Background | Jun 2016 → Dec 2020 | Mycoplasma pneumoniae pneumonia | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02894268 Comparator | Feb 2016 → Oct 2018 | Helicobacter pylori infectious disease | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01951768 Comparator | Sep 2013 → Jun 2016 | ulcer of lower limbs | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 4 | NCT02094703 Background | Apr 2013 → Nov 2014 | urinary tract infection | Dr Cipto Mangunkusumo General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01667718 Background | May → Oct 2012 | dyspepsia, peptic ulcer disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01524302 Comparator | Feb 2012 → May 2014 | bacterial pneumonia | Gary E. Stein, Pharm.D. | Completed | No outcome recorded |
| Phase 4 | NCT01467297 Comparator | Jan → Jun 2012 | chronic obstructive pulmonary disease | University of Milan | Completed | No outcome recorded |
| Phase 4 | NCT01353339 Comparator | Dec 2011 → Feb 2014 | disease related to solid organ transplantation, polyomavirus infectious disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02028754 Background | Jul 2011 → May 2013 | cataract, dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01163435 Comparator | Aug 2010 → Jul 2013 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00873626 Comparator | Jun 2009 → Aug 2011 | urinary tract infection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT01710488 Comparator | May 2009 → Nov 2013 | chronic obstructive pulmonary disease | Fadoi Foundation, Italy | Completed | No outcome recorded |
| Phase 4 | NCT01034176 Comparator | Feb 2009 → Jun 2012 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00840580 Comparator | Jan → Sep 2009 | cataract | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00752947 Comparator | Sep 2008 → Mar 2010 | pneumonia | Beijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00703313 Comparator | May → Jun 2008 | — | Santen Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02123628 Comparator | Jun 2007 → Jun 2010 | diabetes mellitus | Tourcoing Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00155389 Comparator | Jan 2004 → Dec 2015 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00645073 Comparator | Nov 2003 → Mar 2004 | sinusitis | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00665327 Comparator | Nov 2002 → Apr 2004 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase not applicable27 trials | ||||||
| — | NCT07246967 Comparator | Feb 2026 → Mar 2027 expected | urolithiasis | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| — | NCT07179159 Comparator | Sep 2025 → Aug 2026 overdue | Helicobacter pylori infectious disease | Yanqing Li | Recruiting | No outcome recorded |
| — | NCT07126639 Comparator | Sep 2025 → Sep 2027 expected | — | Wuhan Pulmonary Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07130253 Background | Aug 2025 → Jun 2028 expected | Helicobacter pylori infectious disease | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06977347 Comparator | Jun 2025 → Dec 2026 expected | bacterial infectious disease | CHOSEOK YOON | Not yet recruiting | No outcome recorded |
| — | NCT06915688 Comparator | Apr → Jul 2025 overdue | chronic obstructive pulmonary disease | Amina Aslam | Not yet recruiting | No outcome recorded |
| — | NCT06787885 Background | May 2024 → May 2026 | pleural empyema | Fayoum University | Completed | No outcome recorded |
| — | NCT06049758 Comparator | Jan 2024 → Jan 2026 overdue | lymph node disorder | General Committee of Teaching Hospitals and Institutes, Egypt | Not yet recruiting | No outcome recorded |
| — | NCT06199778 Background | Jun 2022 → May 2023 | traumatic brain injury | Zeng Changhao | Terminated | No outcome recorded |
| — | NCT05850117 Comparator | Feb 2020 → Dec 2024 | — | Kaohsiung Medical University | Unknown | No outcome recorded |
| — | NCT04374188 Comparator | Sep 2019 → Sep 2021 | nephrolithiasis | Diaa Eldin Taha Ramadan Mohamed | Unknown | No outcome recorded |
| — | NCT04212403 Comparator | Sep 2018 → Dec 2019 | benign prostatic hyperplasia, diarrheal disease, infectious disease with sepsis, poisoning +1 | Jessa Hospital | Completed | No outcome recorded |
| — | NCT03779087 Background | Jul 2018 → Jun 2020 | Helicobacter pylori infectious disease | Ping-I (William) Hsu, M.D. | Completed | No outcome recorded |
| — | NCT03178292 Comparator | Jun 2017 | infectious disease with sepsis, nephrolithiasis | Mansoura University | Unknown | No outcome recorded |
| — | NCT03257423 Comparator | Apr 2017 → Dec 2022 | appendicitis | Turku University Hospital | Unknown | No outcome recorded |
| — | NCT03236961 Comparator | Apr 2017 → Nov 2018 overdue | appendicitis | Turku University Hospital | Active not recruiting | No outcome recorded |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
| — | NCT02759029 Comparator | Mar 2016 → Feb 2018 | Helicobacter pylori infectious disease | Gangnam Severance Hospital | Unknown | No outcome recorded |
| — | NCT04061447 Comparator | Feb 2016 → May 2019 | Helicobacter pylori infectious disease | Kaohsiung Medical University | Completed | No outcome recorded |
| — | NCT02978157 Background | Feb 2015 → Sep 2017 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT03138785 Background | Jan 2015 → Jun 2017 | — | Farabi Eye Hospital | Unknown | No outcome recorded |
| — | NCT02315547 Background | Jan 2015 → Dec 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| — | NCT02547012 Background | Nov 2013 → Jul 2017 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT01761214 Comparator | Sep 2012 → Dec 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| — | NCT04352062 Background | Jan 2011 → Oct 2018 | — | Medical University of Lodz | Completed | No outcome recorded |
| — | NCT01500837 Comparator | Oct 2010 → Oct 2011 | infective arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01745328 Comparator | Jan 2009 → Mar 2013 | urinary tract infection | Beijing Institute of Disease Control and Prevention | Unknown | No outcome recorded |
Press releases naming this drug 21 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-09-24 | Daiichi Sankyo | Daiichi Sankyo Obtains Approval in Japan for Supplementary Indication of New Quinolone Antibacterial Injection, “Cravit® Intravenous Drip Infusion” daiichisankyo.com ↗ |
| 2015-08-24 | Daiichi Sankyo | Daiichi Sankyo and Daiichi Sankyo Espha Obtain Approval in Japan for Supplementary Indication of “Cravit® Tablets, Granules” and “Levofloxacin Tablets, Granules DSEP” daiichisankyo.com ↗ |
| 2014-10-01 | Daiichi Sankyo | Daiichi Sankyo and Daiichi Sankyo Espha Submit Supplemental New Drug Application in Japan for “Cravit® Tablets, Granules” and “Levofloxacin Tablets, Granules DSEP” daiichisankyo.com ↗ |
| 2014-09-01 | Daiichi Sankyo | Daiichi Sankyo Espha Receives Manufacturing and Marketing License in Japan for “Levofloxacin Tablets 250mg/500mg” and “Granules 10% DSEP” daiichisankyo.com ↗ |
| 2011-01-11 | Daiichi Sankyo | Daiichi Sankyo Launches Cravit(R) Intravenous Injections daiichisankyo.com ↗ |
| 2010-10-27 | Daiichi Sankyo | Daiichi Sankyo receives approval in Japan to manufacture and market Cravit(R) intravenous injections daiichisankyo.com ↗ |
| 2010-10-20 | Daiichi Sankyo | Challenge to US Levofloxacin PTE has Ended daiichisankyo.com ↗ |
| 2010-07-21 | Daiichi Sankyo | Daiichi Sankyo to Leverage Ranbaxy's Network to Market Its Innovative Antibiotic Tavanic® (Levofloxacin) in Romania and South Africa daiichisankyo.com ↗ |
| 2009-11-16 | Daiichi Sankyo | Challenge to UK Levofloxacin SPC and Underlying Patent is Over daiichisankyo.com ↗ |
| 2009-11-09 | Daiichi Sankyo | Regarding the Lawsuit to Revoke the Decision to Nullify a Portion of the Patent Term Extension for Levofloxacin in Japan daiichisankyo.com ↗ |
| 2009-10-29 | Daiichi Sankyo | Daiichi Sankyo Submits Application for Approval of Levofloxacin Hydrate Injection in Japan daiichisankyo.com ↗ |
| 2009-07-07 | Daiichi Sankyo | Daiichi Sankyo Launches new Cravit® Formulations in Japan daiichisankyo.com ↗ |
| 2009-04-22 | Daiichi Sankyo | Daiichi Sankyo Obtains Manufacturing and Marketing Approval for new Cravit® Formulations daiichisankyo.com ↗ |
| 2009-04-09 | Daiichi Sankyo | Daiichi Sankyo Files Patent Infringement Actions against 11 Generics Companies for CRAVIT® TABLETS and FINE GRANULES daiichisankyo.com ↗ |
| 2009-03-23 | Daiichi Sankyo | Daiichi Sankyo Files Patent Infringement Actions against 13 Generics Companies for CRAVIT® TABLTETS and FINE GRANULES daiichisankyo.com ↗ |
| 2008-10-23 | Daiichi Sankyo | UK Levofloxacin SPC and Underlying Patent Upheld by High Court Patent Court daiichisankyo.com ↗ |
| 2007-06-14 | Daiichi Sankyo | Canadian Levofloxacin Patent Upheld by Federal Appeal Court daiichisankyo.com ↗ |
| 2006-10-23 | Daiichi Sankyo | Canadian Levofloxacin Patent Upheld by Federal Judge daiichisankyo.com ↗ |
| 2005-02-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Levofloxacin Injection tevapharm.com ↗ |
| 2005-01-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval Of Levofloxacin Tablets, 750 Mg tevapharm.com ↗ |
| 2004-04-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Levofloxacin Tablets, 250 Mg, 500 Mg, And 750 Mg tevapharm.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 338 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levofloxacin | “Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg...” PMID 16961802 ↗ Oct 2006324“Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗ “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗ “Group 2 will receive azithromycin 500 mg once daily (od) (Truxa®, Laboratorios Monte Verde SA, Argentina), levofloxacin 500 mg od (Laboratorios Asofarma de México SA de CV,...” NCT02726269 ↗ “Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through...” NCT00596167 ↗ “empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes...” NCT07332325 ↗ “patients will receive LOAD therapy comprising of levofloxacin (250 mg with breakfast), omeprazole (40 mg before breakfast), nitazoxanide (Alina) (500 mg twice daily with meals)...” NCT06050824 ↗ “This study aims to evaluate whether adding a fluoroquinolone (levofloxacin or moxifloxacin) to the standard triple therapy improves early clinical outcomes in HIV-infected...” NCT07585461 ↗ “Experimental arms are seven oral regimens with a five-drug combination of the following: bedaquiline, linezolid, a fluoroquinolone (moxifloxacin or levofloxacin), cycloserine,...” NCT05081401 ↗ “Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole...” NCT00885417 ↗ “Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid,...” NCT03565484 ↗ “Patients randomized to antibiotic therapy received intravenous ertapenem (1 g/d) for 3 days followed by 7 days of oral levofloxacin (500 mg once daily) and metronidazole (500...” PMID 26080338 ↗ Jun 2015 “OBJECTIVES: This study assessed the efficacy and safety of a novel aerosol formulation of levofloxacin (MP-376, Aeroquin) in a heavily treated CF population with PA infection.” PMID 21471106 ↗ Feb 2011 “Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)).” NCT05444439 ↗ “If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days.” NCT04061447 ↗ “esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days” NCT05549115 ↗ “Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.” NCT02894268 ↗ “Levofloxacin-sensitive strains: Esomeprazole 20 mg, Bismuth Potassium Citrate 220 mg, Amoxicillin 1 g (twice daily), and Levofloxacin 500 mg (once daily) for 14 days.” NCT06760065 ↗ “Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.” PMID 33427870 ↗ Jan 2021 “Eligible patients were randomised to receive LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day) and lansoprazole (30 mg twice a day) for 7 days” PMID 20427390 ↗ May 2010 “A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention.” NCT01500382 ↗ “Levofloxacin, a quinolone antibiotic, possesses broad-spectrum and potent antibacterial properties, effective in treating intestinal and urinary tract infections.” NCT06571097 ↗ “The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.).” NCT01761214 ↗ “The investigational MDR-END Plus regimen consists of oral anti-tuberculosis drugs including bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide.” NCT07675954 ↗ “Patients resistant to clarithromycin but sensitive to levofloxacin are assigned to the Levofloxacin Group (receiving vonoprazan, amoxicillin, and levofloxacin)” NCT07533422 ↗ “Arm 2 participants will receive high-dose rifampicin plus levofloxacin for 8 weeks, in addition to standard doze pyrazinamide and isoniazid.” NCT02958709 ↗ “vonoprazan 20 mg twice daily (30 minutes before meal), Amoxicillin 1 g twice daily (After meal), Levofloxacin 500 mg once daily for 14 days” NCT07537634 ↗ “priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.” NCT02689583 ↗ “Patients were randomized to receive either clarithromycin, esomeprazole, and amoxicillin, or levofloxacin, esomeprazole, and amoxicillin.” PMID 36670359 ↗ Jan 2023 “including Tegoprazan , Amoxicillin, Clarithromycin, Levofloxacin, Bismuth Potassium Citrate, Metronidazole, Doxycycline or Minocycline.” NCT07405684 ↗ “In the event of allergy to ceftriaxone, it will be replaced by levofloxacin (500 mg/24 h in one intravenous injection, for 3 days).” PMID 32487213 ↗ Jun 2020 “Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml, Vancomycin 1mg/ml, Tobramycin 0.7mg/ml, Levofloxacin 0.4mg/ml” NCT03935828 ↗ “Antibiotics are selected from Amoxicillin, Tetracycline, Furazolidone, Levofloxacin, Clarithromycin, Tinidazole, Metronidazole.” NCT05133193 ↗ “In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given.” NCT03556254 ↗ “Levofloxacin Tablets: 0.5 g/tablet. 0.5 g (1 tablet) orally once daily within 1 hour before breakfast for 8 weeks (56 days).” NCT06889701 ↗ “MP-376 (Aeroquin™) is a novel formulation of the fluoroquinolone levofloxacin that has been optimized for aerosol delivery.” NCT01180634 ↗ “levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days” NCT05332444 ↗ “Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months” NCT01677871 ↗ “esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.” NCT03779087 ↗ “Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.” NCT01745328 ↗ “including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).” NCT01805934 ↗ “levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week)” NCT03391440 ↗ “Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin” NCT03409679 ↗ “Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.” NCT07170800 ↗ “oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)” NCT03220074 ↗ “Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or quadruple therapy” NCT07130253 ↗ “Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days” NCT05184491 ↗ “levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.” NCT03038321 ↗ “Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.” NCT03658291 ↗ “Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.” NCT03619252 ↗ “Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h” NCT01951768 ↗ “The fluoroquinolone antibiotics included ciprofloxacin, levofloxacin, and moxifloxacin.” NCT04879030 ↗ “Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid” NCT04626193 ↗ “esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.” NCT02978157 ↗ “Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment” NCT02315547 ↗ “rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days” NCT01163435 ↗ “per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days” NCT03234296 ↗ “Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group” NCT02648698 ↗ “Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times” NCT04660123 ↗ “tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days” NCT02547025 ↗ “tienam,meropenem,levofloxacin,ciprofloxacin,amikacin,gentamicin” NCT03622450 ↗ “Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily” NCT02120638 ↗ “Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily” NCT03867136 ↗ “a second-generation cephalosporin or levofloxacin” NCT07246967 ↗ “* PRO-174. Levofloxacin 0.5% ophthalmic solution.” NCT03519516 ↗ “ethambutol, levofloxacin, moxifloxacin, ofloxacin” NCT03237182 ↗ “WHO levofloxacin-strengthened regimen (6EHRZLfx)” NCT03862248 ↗ “* Levofloxacin (PO) : 500mg ot 1g/ twice a day” NCT05074147 ↗ “* Levofloxacin IV and PO 500-750mg once daily” NCT02123628 ↗ “oral levofloxacin tablets, 0.5 g once daily” NCT07512648 ↗ “Levofloxacin 500 mg tablets once daily” NCT06101420 ↗ “Levofloxacin 500mg, PO, QD, 1wk” NCT02759029 ↗ “levofloxacin 250mg twice daily” NCT04713670 ↗ “Levaquin=Levofloxacin” NCT01074554 ↗ “levofloxacin 500 mg” NCT02547012 ↗ “Levofloxacin” NCT02099240 ↗ |
| Known as | Aeroquin | “MP-376 (Aeroquin™) is a novel formulation of the fluoroquinolone levofloxacin that has been optimized for aerosol delivery.” NCT01180634 ↗ |
| Known as | Cravit | “Levofloxacin(Cravit), Amoxicillin/clavulanate(Augmentin) and” NCT01575899 ↗ |
| Known as | Cravit 0.5% | “patients with senile cataracts who were undergoing phacoemulsification were assigned to receive intracameral levofloxacin (0.1 ml/0.5 mg; Cravit® 0.5%; Santen Pharmaceutical...” PMID 41038947 ↗ Oct 2025 |
| Known as | DE-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02573610 ↗ |
| Known as | Generic name: Levofloxacin | “Generic name: Levofloxacin” NCT01761201 ↗ |
| Known as | HR355 | “Levofloxacin (HR355) and Rifampicin Therapy” NCT00906048 ↗ |
| Known as | LEV | “The purpose of this study was to compare the efficacy and safety of TGC with levofloxacin (LEV) in adult hospitalised patients with community-acquired pneumonia (CAP) in a...” PMID 19036672 ↗ Oct 2008 |
| Known as | Levaquin | “Groups 4, 5 and 6 received the same treatment with the corresponding oral dose of ofloxacin 400 mg (Floxin), ciprofloxacin 400 mg (Cipro) and levofloxacin 250 mg (Levaquin).” PMID 18211932 ↗ Jan 20083“The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole” NCT03303677 ↗ “Intravenous Levaquin initially, then oral dosing.” NCT03768869 ↗ |
| Known as | Levaquin (levofloxacin) | “Levaquin (levofloxacin)” NCT00596167 ↗1“Levaquin=Levofloxacin” NCT01074554 ↗ |
| Known as | LEVO | “In this open-labeled, randomized clinical trial, the Investigator will assess the safety and pharmacokinetics (PK) of model-optimized doses of rifampicin (RIF) with or without...” NCT02958709 ↗ |
| Known as | Levofloxacin hydrate | “Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.” NCT04212429 ↗1“Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.” NCT04214821 ↗ |
| Known as | Levofloxacin hydrochloride | “Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.” NCT02439632 ↗ |
| Known as | Levofloxacin Ocular Implant | “Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.” NCT05441930 ↗ |
| Known as | Levofloxacin Ophthalmic Solution | “Levofloxacin Ophthalmic Solution” NCT03519516 ↗ |
| Known as | levofloxacin tablets | “The experimental group receives Sanjin tablets plus levofloxacin tablets (LT) placebo” PMID 31324199 ↗ Jul 2019 |
| Known as | LFX | “Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB).” PMID 23927582 ↗ Oct 20132“6-month all-oral regimen, consisting of Bedaquiline (BDQ, B), Delamanid (DLM, D), Linezolid (LZD, L), Levofloxacin (LFX) , as known as BDLL regimen” NCT07198685 ↗ “The FQs - sensitive group was treated with the BDLL regimen (bedaquiline (BDQ), delamanid (DLM), linezolid (LZD), and levofloxacin (LFX))” NCT07126639 ↗ |
| Known as | LVFX | “In vitro studies have suggested the corneal cytotoxicity of third-generation fluoroquinolone levofloxacin (LVFX) and fourth-generation fluoroquinolone moxifloxacin...” PMID 21060669 ↗ Oct 20101“levofloxacin [LVFX]” NCT02365623 ↗ |
| Known as | MP-376 | “OBJECTIVES: This study assessed the efficacy and safety of a novel aerosol formulation of levofloxacin (MP-376, Aeroquin) in a heavily treated CF population with PA infection.” PMID 21471106 ↗ Feb 20114“MP-376 (Aeroquin™) is a novel formulation of the fluoroquinolone levofloxacin that has been optimized for aerosol delivery.” NCT01180634 ↗ “MP-376 (Levofloxacin solution for Inhalation)” NCT00840333 ↗ “MP-376 (Levofloxacin solution for Inhalation)” NCT00752414 ↗ “MP-376 (Levofloxacin solution for Inhalation)” NCT00503490 ↗ |
| Known as | PRO-174 | “* PRO-174. Levofloxacin 0.5% ophthalmic solution.” NCT03519516 ↗ |
| Known as | Quixin | “Groups 1, 2 and 3 received topical ofloxacin 0.3% (Ocuflox), ciprofloxacin 0.3% (Ciloxan) and levofloxacin (Quixin) respectively;” PMID 18211932 ↗ Jan 2008 |
| Known as | Tavanic | “Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB.” NCT00495339 ↗3“(Tavanic ''levofloxacin 500 mg'') [Sanofi-Aventis - Egypt]” NCT03038321 ↗ “levofloxacin (Tavanic) orally or no antibiotics” NCT04212403 ↗ |
| Modality | Small molecule | “a fluoroquinolone” NCT00376376 ↗ |
| Route | Oral | “Patients receive oral levofloxacin once daily for 7 consecutive days” NCT00005590 ↗ |